S-444,823

S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist.[1] It was developed as an antipruritic, and has moderate selectivity for the CB2 subtype, having a CB2 affinity of 18nM, and 32x selectivity over the CB1 receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists.[2]

S-444,823
Clinical data
ATC code
  • none
Identifiers
  • 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H33N3O4S
Molar mass471.62 g·mol−1
3D model (JSmol)
  • O=C(C(C(NC1=NC(CCC(O)=O)=CS1)=O)=C2)N(CC3CCCCC3)C4=C2CCCCCC4
  • InChI=1S/C25H33N3O4S/c29-22(30)13-12-19-16-33-25(26-19)27-23(31)20-14-18-10-6-1-2-7-11-21(18)28(24(20)32)15-17-8-4-3-5-9-17/h14,16-17H,1-13,15H2,(H,29,30)(H,26,27,31)
  • Key:SYBONVBDFTYUQP-UHFFFAOYSA-N

See also

References
  1. Arimura A. Novel Use of Cannabinoid Receptor Agonist. Patent WO 2005/016351
  2. Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, et al. (April 2012). "Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent". Bioorganic & Medicinal Chemistry Letters. 22 (8): 2898–901. doi:10.1016/j.bmcl.2012.02.050. PMID 22421019.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.